CNDP1 Protein & Antibody

Carnosine Dipeptidase 1

CNDP1 Products

CNDP1 Protein, Recombinant

Molecule	Species	Description	Cat. No
CNDP1	Human	CNDP1/Fc Protein, Recombinant	10077-H03H
CNDP1	Human	CNDP1 Protein, Recombinant	10077-H08H
CNDP1	Mouse	CNDP1 Protein, Recombinant	50959-M08H

CNDP1 Antibody

Molecule	Application	Description	Cat. No
Human CNDP1	ELISA	Mouse Monoclonal Antibody Mab	10077-MM01
Human CNDP1	WB	Mouse Monoclonal Antibody Mab	10077-MM02
Human CNDP1	ELISA	Rabbit Polyclonal Antibody	10077-RP03
Human CNDP1	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	10077-RP04
Mouse CNDP1	WB, ELISA	Rabbit Monoclonal Antibody Mab	10077-R001

CNDP1 cDNA Clone

Molecule	Species	Description	Cat. No
CNDP1	Human	Homo sapiens CNDP1 cDNA Clone(NM_032649.5)	HG10077-M
CNDP1	Mouse	Mouse CNDP1 cDNA Clone / ORF Clone	MG50959-G

CNDP1 Related Areas

Enzyme>>Protease & Regulator>>Metalloprotease & Regulator>>CNDP1

CNDP1 Alternative Names

CNDP1, CN1, CPGL2, HsT2308, MGC102737, MGC10825, MGC142072 [Homo sapiens]

Cndp1, Cn1, AI746433 [Mus musculus]

CNDP1 Background

CNDP1, also known as carnosine dipeptidase 1, glutamate carboxypeptidase-like protein 2 (CPGL-2) or carnosinase 1 (CN1), is a member of the M20 metalloprotease family. The CNDP1 gene contains trinucleotide (CTG) repeat length polymorphism in the coding region, which has been demonstrated to be associated with susceptibility to developing diabetic nephropathy, for carnosine protection against the adverse effects of high glucose levels on renal cells. In humans, CNDP1 is secreted from the liver into the serum. In other mammals, including rodents, CNDP1 is expressed exclusively within the kidney and lacks a signal peptide. CNDP1 protein is a secreted homodimeric dipeptidase that specifically hydrolyzes L-carnosine (β-alanyl-L-histidine), and is identified as human carnosinase expressed in the brain. CNDP1 has been associated with diabetic nephropathy in Europeans and European Americans, but not African-Americans. It was identified and confirmed as a risk factor, were cross-sectional and mostly in patients with type 2 diabetes. The polymorphisms of CNDP1 can be excluded as a risk factor for nephropathy in type 1 diabetes. In addition, CNDP1 is also suggested to be implicated in the actions of neuroprotection and neurotransmiting.

CNDP1 Related Studies

1. Teufel M, et al. (2003) Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 278(8):6521-31.
2. Janssen B, et al. (2005) Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54(8):2320-7.
3. Riedl E, et al. (2007) A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. Diabetes 56(9):2410-3.
4. Freedman BI, et al. (2007) A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant 22(4):1131-5.
5. Wanic K, et al. (2008) Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. Diabetes 57(9):2547-51.
6. McDonough CW, et al. (2009) The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans. Hum Genet. 126(2):265-75.